Proactive Vision Analysis
Let's Assess AMD Risk Years Before Vision Loss
💡 Executive Summary
Age-related Macular Degeneration (AMD) is the #1 cause of vision impairment and severe vision loss among elderly people in the United States.
Our groundbreaking solution enables disease risk determination years before vision loss.
Unique Value Proposition
Key Investment Metrics
Market Opportunity: Inspired by the Exact Sciences model ($20.0 billion market value, $2.76 billion annual revenue, currently planned for acquisition by Abbott), we are positioned to capture significant market share in the high-impact healthcare sector.
💡 Phase 1 Detailed Milestones
Phase 1: Validation and CLIA Commercialization Preparation
Phase 1 Key Milestones
CLIA Certification Strategy
Proactive Vision Analysis
Let's Assess AMD Risk Years Before Vision Loss
💡 Critical Problem
Current detection methods identify the disease only after irreversible damage has occurred, when treatment options are limited and costly.
Disease Progression Stages
AMD progresses through four distinct stages: Early Stage (mild central vision changes), Intermediate Stage (increasing central vision loss), Advanced Dry AMD (significant central vision loss), and Advanced Wet AMD (severe central vision loss with rapid progression). Current screening methods detect the disease far too late in this progression.
Critical Challenge: Progressive and irreversible vision loss occurs over time. When vision problems become apparent, the damage is permanent and irreversible.
💡 Early Risk Assessment Opportunity
Chronic diseases develop silently over years before symptoms appear. This creates a critical window of opportunity for early intervention.
Navigate through the five interactive visualizations below to explore disease progression and early detection opportunities.
Proof-of-Concept Success
Breakthrough Results in Native Peptide Biomarker Discovery
398 Biomarkers Discovered
Statistically significant potential biomarkers identified (p<0.05)
11 Top Biomarkers
High-confidence biomarkers with p<0.003 and Fold Changes >10
Technical Validation
Attomole sensitivity detection validates our technical approach
Scalability Proven
Results demonstrate feasibility for larger validation studies
Statistical Analysis & Power Analysis
Statistical Methods: Statistical analyses were performed using Python Version 3.12.4 with libraries (NumPy, SciPy, Pandas, and Matplotlib) and GraphPad Prism Software. The Shapiro-Wilk test was used to determine the distribution of continuous variables in each group. For comparing two groups, Welch's t-test was applied if both groups showed normal distributions, while the Mann-Whitney U test was used if at least one group had a non-normal distribution. To control for multiple comparisons, we applied the Benjamini-Hochberg procedure with a False Discovery Rate (FDR) of 1%.
Power Analysis & Sample Size Calculation: Based on our proof-of-concept study data, power analysis (Cohen's d effect size calculations) was performed. A sample size of 60 subjects per group will be needed to provide >90% power to detect significant differences between groups (alpha = 0.05). Groups are Age-matched Older Healthy Subjects, Early Dry AMD, Late Dry AMD, Wet AMD. For the full validation study, we plan to enroll 240 total samples to ensure robust statistical power across multiple biomarker comparisons.
Data Visualization: Volcano plots were generated using Matplotlib and Seaborn libraries, highlighting significantly regulated peptides (p < 0.05, |log2FoldChange| > 2). These visualizations demonstrate clear separation between biomarker expression levels in AMD patients versus healthy subjects, validating the diagnostic potential of our platform.
Early Detection Window: This visualization demonstrates how diseases progress gradually over many years. Our blood-based risk assessment platform can detect biological changes during the early phase—years before traditional diagnostic methods identify symptoms—enabling timely intervention when treatment is most effective.
💡 Our Breakthrough Solution
The current standard of care is symptom-driven—people seek treatment only after vision loss occurs.
Our platform enables early risk assessment through a simple blood test during routine family doctor visits.
Unique Value Proposition
💡 Proof-of-Concept Success
Our proof-of-concept study demonstrates breakthrough results in identifying native peptide biomarkers for wet AMD detection and risk assessment.
398 Biomarkers Discovered
Statistically significant potential biomarkers identified (p<0.05)
11 Top Biomarkers
High-confidence biomarkers with p<0.003 and Fold Changes >10
Technical Validation
Attomole sensitivity detection validates our technical approach
Scalability Proven
Results demonstrate feasibility for larger validation studies
💡 Proven Business Model
Our business model is inspired by the highly successful Exact Sciences model, which achieved a $20.0 billion market value and $2.76 billion annual revenue through blood-based diagnostic tests. Exact Sciences is currently planned for acquisition by Abbott.
Inspiration for Our Business Strategy
Exact Sciences Analysis - 2025 Growth Strategy
Understanding EBITDA Growth
$315M+ Adjusted EBITDA in 2024 represents earnings before interest, taxes, depreciation and amortization, adjusted for non-recurring items. 44% annual growth demonstrates strong operational performance and improved profitability compared to 2023.
2024 Revenue Distribution
2025 Product Portfolio: $58B Target Market Volume
💡 US Insurance Reimbursement Pathway
In US, Medicare covers the cost of tests performed before disease onset. Our AMD risk assessment test can also be covered after necessary procedures.
💡 Stakeholder Interest & Path to Market
U.S. Department of Health & Human Services
✓ Regulatory pathway interest
ARVO Conference
Association for Research in Vision and Ophthalmology
✓ Scientific community interest
MARK CUBAN
Shark Tank
✓ Commercial distribution interest
Physicians Ready to Collaborate
AI Healthcare Conference at Stanford University
💡 Market Opportunity Analysis
Market Calculation: 169.1 million target population × $250 test price = $42.3 billion total addressable market
📋 Market Sizing Methodology: Bottom-up analysis using U.S. Census Bureau demographic data, CMS healthcare engagement statistics, AMD risk factor prevalence studies (NEI, AAO), and insurance coverage rates. SAM reflects serviceable market accounting for insurance coverage, healthcare access, and proactive health engagement patterns.
